The use of vasopressin receptor antagonists in hyponatremia

Expert Opinion on Investigational Drugs

Volumn 20, Issue 3, 2011, Pages 373-380

  Elhassan, Elwaleed A ^a   Schrier, Robert W ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

aquaretics; hyponatremia; vaptans; vasopressin receptor antagonists

Indexed keywords

CONIVAPTAN; DEMECLOCYCLINE; DESMOPRESSIN; FUROSEMIDE; LITHIUM; LIXIVAPTAN; LOOP DIURETIC AGENT; PLACEBO; SATAVAPTAN; THIAZIDE DIURETIC AGENT; TOLVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST;

BONE DENSITY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DIURESIS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; EXTRACELLULAR FLUID; FLUID INTAKE; FRACTURE; HEART FAILURE; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; LIVER CIRRHOSIS; MICTURITION; NEPHROTOXICITY; NONHUMAN; OSTEOPOROSIS; POLYURIA; REVIEW; RISK FACTOR; SIDE EFFECT; SODIUM EXCRETION; THIRST; TREATMENT OUTCOME; UREMIA; XEROSTOMIA;

ANIMALS; BENZAZEPINES; CHRONIC DISEASE; HUMANS; HYPONATREMIA; RECEPTORS, VASOPRESSIN;

EID: 79951656898     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.553186     Document Type: Review

References (50)

1. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med 2006;119(7 Suppl 1):S30-5
2. Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta 2003;337(1-2):169-72 (Pubitemid 37329815)
3. Bennani SL, Abouqal R, Zeggwagh AA, et al. Incidence, causes and prognostic factors of hyponatremia in intensive care. Rev Med Interne 2003;24:224-9 (Pubitemid 36542165)
4. Wald R, Jaber BL, Price LL, et al. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med 2010;170(3):294-302
5. Sajadieh A, Binici Z, Mouridsen MR, et al. Mild hyponatremia carries a poor prognosis in community subjects. Am J Med 2009;122(7):679-86
6. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 2009;122(9):857-65
7. Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006;119(1): 71.e1-71.e8
8. Gankam Kengne F, Andres C, Sattar L, et al. Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM 2008;101:583-8 (Pubitemid 351912001)
9. Kinsella S, Moran S, Sullivan MO, et al. Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clin J Am Soc Nephrol 2010;5:275-80
10. Sandhu HS, Gilles E, DeVita MV, et al. Hyponatremia associated with large bone fracture in elderly patients. Int Urol Nephrol 2009;41:733-7
11. Schrier RW. Body water homeostasis: clinical disorders of urinary dilution and concentration. J Am Soc Nephrol 2006;17(7):1820-32 (Pubitemid 44036166)
12. Ellis SJ. Severe hyponatraemia: complications and treatment. QJM 1995;88(12):905-9 (Pubitemid 26009659)
13. Sterns RH, Nigwekar SU, Hix JK. The treatment of hyponatremia. Semin Nephrol 2009;29(3):282-99
14. Roh JH, Kim JH, Oh K, et al. Cortical laminar necrosis caused by rapidly corrected hyponatremia. J Neuroimaging 2009;19(2):185-7
15. Odier C, Nguyen DK, Panisset M. Central pontine and extrapontine myelinolysis: from epileptic and other manifestations to cognitive prognosis. J Neurol 2010;257(7):1176-80
16. Sterns RH, Hix JK, Silver S. Treatment of hyponatremia. Curr Opin Nephrol Hypertens 2010;19(5):493-8
17. Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007;120(11 Suppl 1):S1-21
18. Berl T, Rastegar A. A patient with severe hyponatremia and hypokalemia: osmotic demyelination following potassium repletion. Am J Kidney Dis 2010;55(4):742-8
19. Karp BI, Laureno R. Pontine and extrapontine myelinolysis: a neurologic disorder following rapid correction of hyponatremia. Medicine 1993;72:359-73 (Pubitemid 23345633)
20. Sterns RH, Hix JK. Overcorrection of hyponatremia is a medical emergency. Kidney Int 2009;76(6):587-9
21. Perianayagam A, Sterns RH, Silver SM, et al. DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia. Clin J Am Soc Nephrol 2008;3(2):331-6
22. Verbalis JG, Barsony J, Sugimura Y, et al. Hyponatremia-induced osteoporosis. J Bone Miner Res 2010;25:554-63
23. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355(20):2099-112 (Pubitemid 44749318)
24. Schrier RW. Does 'asymptomatic hyponatremia' exist? Nat Rev Nephrol 2010;6:185
25. Rosner MH. Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors. Am J Med Sci 2004;327(2):109-11 (Pubitemid 38220479)
26. Cherrill DA, Stote RM, Birge JR, Singer I. Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion. Ann Intern Med 1975;83:654-6
27. Dousa TP, Wilson DM. Effects of demethylchlortetracycline on cellular action of antidiuretic hormone in vitro. Kidney Int 1974;5:279-84
28. Miller PD, Linas SL, Schrier RW. Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients. JAMA 1980;243:2513-15 (Pubitemid 10039244)
29. Zegers de Beyl D, Naeije R, de Troyer A. Demeclocycline treatment of water retention in congestive heart failure. BMJ 1978;1:760 (Pubitemid 8318333)
30. Decaux G, Mols P, Cauchi P, Delwiche F. Use of urea for treatment of water retention in hyponatraemic cirrhosis with ascites resistant to diuretics. BMJ (Clin Res Ed) 1985;290:1782-3 (Pubitemid 15059210)
31. Decaux G, Andres C, Gankam Kengne F, Soupart A. Treatment of euvolemic hyponatremia in the intensive care unit by urea. Crit Care 2010;14(5):R184
32. Decaux G, Waterlot Y, Genette F, et al. Inappropriate secretion of antidiuretic hormone treated with frusemide. Br Med J (Clin Res Ed) 1982;285(6335):89-90 (Pubitemid 12075526)
33. Forrest JN Jr, Cox M, Hong C, et al. Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med 1978;298:173-7 (Pubitemid 8272273)
34. Velez JC, Dopson SJ, Sanders DS, et al. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience. Nephrol Dial Transplant 2010;25(5):1524-31
35. Ghali JK, Koren MJ, Tylor JR, et al. Conivaptan study group. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006;91:2145-52 (Pubitemid 43854997)
36. Li-Ng M, Verbalis JG. Conivaptan: evidence supporting its therapeutic use in hyponatremia. Core Evid 2010;4:83-92
37. Berl T, Quittnat-Pelletier F, Verbalis JG, et al. SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010;21(4):705-12
38. Greenberg A, Lehrich RW. Treatment of chronic hyponatremia: now we know how, but do we know when or if? J Am Soc Nephrol 2010;21(4):552-5
39. Verbalis JG, Adler S, Schrier RW, et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol in press
40. Martin PY, Abraham WT, Leiming X, et al. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol 1999;10:2165-70 (Pubitemid 29453494)
41. Gheorghiade M, Abraham WT, Albert NM, et al. OPTIMIZE-HF Investigators and Coordinators. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 2007;28(8):980-8 (Pubitemid 47343897)
42. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003;290(19):2581-7 (Pubitemid 37443288)
43. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005;46:1785-91 (Pubitemid 41579797)
44. Thibonnier M, Conarty DM, Preston JA, et al. Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol 1998;449:251-76 (Pubitemid 28566397)
45. Abraham WT, Aranda JM, Boehmer JP, et al. Rationale and Design of the Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation (THE BALANCE) Study. Clin Transl Sci 2010;3(5):249-53
46. Heuman DM, Abou-assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at risk for early death. Hepatology 2004;40:802-10 (Pubitemid 39288112)
47. Okita K, Sakaida I, Okada M, et al. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterology 2010;45(9):979-87
48. O'Leary JG, Davis GL. Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease. Liver Transpl 2009;15(10):1325-9
49. Wong F, Gines P, Watson H, et al. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol 2010;53(2):283-90
50. Veeraveedu PT, Palaniyandi SS, Yamaguchi K, et al. Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents. Drug Discov Today 2010;15(19-20):826-41